The HEG1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human colorectal adenocarcinoma HT-29 cell line. This product provides a loss-of-function model for HEG1, a gene encoding a transmembrane co-receptor with multiple EGF-like domains essential for BMP signaling, angiogenesis, and cell adhesion. The polyclonal population comprises a heterogeneous mix of cells carrying distinct gene disruptions, offering a robust tool for investigating HEG1 function without the clonal variability of single-cell-derived lines.
The HT-29 cell line, isolated from a primary colorectal adenocarcinoma, exhibits epithelial morphology and is widely employed as a model system for intestinal epithelial biology and colorectal cancer studies. These cells retain characteristic features of transformed epithelial cells, making them suitable for investigating tumorigenic processes, drug responses, and signal transduction pathways relevant to colorectal carcinoma.
HEG1 functions as an essential co-receptor in BMP9/10 signaling, interacting with the ACVRL1 (ALK1) type I receptor, endoglin (ENG), and BMPR2 receptor complex on the cell surface. Upon ligand binding, HEG1 potentiates the phosphorylation of SMAD1/5/8 transcription factors, which then associate with SMAD4 to promote the expression of pro-angiogenic target genes such as ID1 and ID3. This signaling axis is modulated by upstream inputs including the ERG transcription factor, Notch signaling, and shear stress, and it orchestrates key processes like endothelial cell migration and proliferation. Dysregulation of this pathway is implicated in hereditary hemorrhagic telangiectasia (HHT), arteriovenous malformations, and congenital heart defects.
In the HT-29 colorectal adenocarcinoma background, HEG1 knockout provides a physiologically relevant model to dissect its contributions to epithelial tumor biology. HEG1 has been associated with cell adhesion and migration, processes that are critical for cancer invasion and metastasis. Disruption of HEG1 in these cells enables investigation of altered BMP/TGF-beta pathway activity in a colorectal cancer context, revealing potential roles in epithelial-mesenchymal transition, tumor-stroma interactions, and responses to microenvironmental cues.
Researchers can utilize this knockout cell population to examine HEG1 function through a variety of assays, including Western blotting and RT-qPCR for expression analysis of downstream targets like ID1 and ID3, Transwell assays to assess cell migration and invasion, and MTT proliferation assays to evaluate growth effects. Co-immunoprecipitation can probe interactions with ALK1 or endoglin, while RNA-seq and pathway reporter assays offer system-wide views of transcriptional reprogramming. These cells are also suitable for in vivo tumor formation studies via xenograft models, enabling exploration of HEG1??s role in tumor progression and angiogenesis. For further information or to discuss potential applications, please contact Ascent Research.
